BioLineRx Ltd. (NASDAQ:BLRX) – Roth Capital cut their FY2016 earnings estimates for BioLineRx in a research report issued on Tuesday. Roth Capital analyst J. Pantginis now forecasts that the brokerage will post earnings of ($0.28) per share for the year, down from their prior forecast of ($0.27). Roth Capital has a “Buy” rating and a $7.00 price objective on the stock. Roth Capital also issued estimates for BioLineRx’s FY2017 earnings at ($0.32) EPS.
Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of BioLineRx from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Monday, August 15th. Maxim Group lowered shares of BioLineRx from a “buy” rating to a “hold” rating and decreased their target price for the stock from $4.00 to $1.00 in a research note on Friday, August 12th. Finally, S&P Equity Research decreased their target price on shares of BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $2.68.
Shares of BioLineRx (NASDAQ:BLRX) opened at 1.08 on Thursday. The company has a 50 day moving average price of $0.00 and a 200-day moving average price of $0.00. BioLineRx has a one year low of $0.71 and a one year high of $1.63.
Hedge funds have recently made changes to their positions in the company. Senvest Management LLC increased its stake in shares of BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares in the last quarter. KCG Holdings Inc. increased its stake in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock worth $174,000 after buying an additional 121,650 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares in the last quarter. Institutional investors and hedge funds own 14.35% of the company’s stock.